Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 50.54%: Here's is How to TradeZacks Investment Research • 01/04/24
Dyne Therapeutics stock gains, Sarepta falls after muscular dystrophy trial resultsMarket Watch • 01/03/24
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/02/24
Sarepta (SRPT): Strong Industry, Solid Earnings Estimate RevisionsZacks Investment Research • 12/29/23
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory StatusBusiness Wire • 12/22/23
Wall Street Analysts See a 53.71% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?Zacks Investment Research • 12/15/23
Sarepta Therapeutics (SRPT) Up 4.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/01/23
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 82.64%: Read This Before Placing a BetZacks Investment Research • 11/29/23
Huge Insider Buys at Energy Giants, Bill Ackman Boosts Real Estate Stake Again24/7 Wall Street • 11/14/23
Here's Why Sarepta Therapeutics (SRPT) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 11/13/23
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPTPRNewsWire • 11/05/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTPRNewsWire • 11/03/23